<?xml version='1.0' encoding='utf-8'?>
<document id="26721703"><sentence text="Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions." /><sentence text="During the last 10-15 years, cytochrome P450 (CYP) 2C8 has emerged as an important drug-metabolizing enzyme" /><sentence text=" CYP2C8 is highly expressed in human liver and is known to metabolize more than 100 drugs" /><sentence text=" CYP2C8 substrate drugs include amodiaquine, cerivastatin, dasabuvir, enzalutamide, imatinib, loperamide, montelukast, paclitaxel, pioglitazone, repaglinide, and rosiglitazone, and the number is increasing"><entity charOffset="32-43" id="DDI-PubMed.26721703.s4.e0" text="amodiaquine" /><entity charOffset="45-57" id="DDI-PubMed.26721703.s4.e1" text="cerivastatin" /><entity charOffset="59-68" id="DDI-PubMed.26721703.s4.e2" text="dasabuvir" /><entity charOffset="70-82" id="DDI-PubMed.26721703.s4.e3" text="enzalutamide" /><entity charOffset="84-92" id="DDI-PubMed.26721703.s4.e4" text="imatinib" /><entity charOffset="94-104" id="DDI-PubMed.26721703.s4.e5" text="loperamide" /><entity charOffset="106-117" id="DDI-PubMed.26721703.s4.e6" text="montelukast" /><entity charOffset="119-129" id="DDI-PubMed.26721703.s4.e7" text="paclitaxel" /><entity charOffset="131-143" id="DDI-PubMed.26721703.s4.e8" text="pioglitazone" /><entity charOffset="145-156" id="DDI-PubMed.26721703.s4.e9" text="repaglinide" /><entity charOffset="162-175" id="DDI-PubMed.26721703.s4.e10" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e0" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e1" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e2" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e3" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e4" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e5" e2="DDI-PubMed.26721703.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e5" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e5" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e5" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e5" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e5" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e6" e2="DDI-PubMed.26721703.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e6" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e6" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e6" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e6" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e7" e2="DDI-PubMed.26721703.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e7" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e7" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e7" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e8" e2="DDI-PubMed.26721703.s4.e8" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e8" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e8" e2="DDI-PubMed.26721703.s4.e10" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e9" e2="DDI-PubMed.26721703.s4.e9" /><pair ddi="false" e1="DDI-PubMed.26721703.s4.e9" e2="DDI-PubMed.26721703.s4.e10" /></sentence><sentence text=" Similarly, many drugs have been identified as CYP2C8 inhibitors or inducers" /><sentence text=" In vivo, already a small dose of gemfibrozil, i"><entity charOffset="34-45" id="DDI-PubMed.26721703.s6.e0" text="gemfibrozil" /></sentence><sentence text="e" /><sentence text=", 10% of its therapeutic dose, is a strong, irreversible inhibitor of CYP2C8" /><sentence text=" Interestingly, recent findings indicate that the acyl-β-glucuronides of gemfibrozil and clopidogrel cause metabolism-dependent inactivation of CYP2C8, leading to a strong potential for drug interactions"><entity charOffset="50-69" id="DDI-PubMed.26721703.s9.e0" text="acyl-β-glucuronides" /><entity charOffset="73-84" id="DDI-PubMed.26721703.s9.e1" text="gemfibrozil" /><entity charOffset="89-100" id="DDI-PubMed.26721703.s9.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.26721703.s9.e0" e2="DDI-PubMed.26721703.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26721703.s9.e0" e2="DDI-PubMed.26721703.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26721703.s9.e0" e2="DDI-PubMed.26721703.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26721703.s9.e1" e2="DDI-PubMed.26721703.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26721703.s9.e1" e2="DDI-PubMed.26721703.s9.e2" /></sentence><sentence text=" Also several other glucuronide metabolites interact with CYP2C8 as substrates or inhibitors, suggesting that an interplay between CYP2C8 and glucuronides is common"><entity charOffset="20-31" id="DDI-PubMed.26721703.s10.e0" text="glucuronide" /><entity charOffset="142-154" id="DDI-PubMed.26721703.s10.e1" text="glucuronides" /><pair ddi="false" e1="DDI-PubMed.26721703.s10.e0" e2="DDI-PubMed.26721703.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26721703.s10.e0" e2="DDI-PubMed.26721703.s10.e1" /></sentence><sentence text=" Lack of fully selective and safe probe substrates, inhibitors, and inducers challenges execution and interpretation of drug-drug interaction studies in humans" /><sentence text=" Apart from drug-drug interactions, some CYP2C8 genetic variants are associated with altered CYP2C8 activity and exhibit significant interethnic frequency differences" /><sentence text=" Herein, we review the current knowledge on substrates, inhibitors, inducers, and pharmacogenetics of CYP2C8, as well as its role in clinically relevant drug interactions" /><sentence text=" In addition, implications for selection of CYP2C8 marker and perpetrator drugs to investigate CYP2C8-mediated drug metabolism and interactions in preclinical and clinical studies are discussed" /><sentence text=" " /></document>